Formulation Development For Therapeutic Oligonucleotides

Formulation development for oligonucleotide-based therapies demands a deep understanding of both the molecules themselves and the delivery routes they require. With expertise across all classes of oligonucleotides—including ASOs, siRNA, and PMO/PPMO — and delivery methods ranging from intrathecal to subcutaneous, Pace combines scientific insight with extensive hands-on experience. A critical part of their approach involves robust analytical capabilities that support the characterization and stability testing of candidate formulations.

Formulations such as antibody-oligonucleotide conjugates, lipid nanoparticles (LNPs), and other nanoparticle systems are developed with attention to key parameters like osmolality, pH, and viscosity—factors that influence performance and syringeability. Empirical evaluation of each oligonucleotide’s behavior in solution ensures accurate control of formulation characteristics.

Support extends beyond R&D to include GMP stability studies, material compatibility testing, and the development of scalable compounding procedures. Manufacturing for GLP studies and tech transfer to internal or external partners is also offered. Learn more about how expert-driven formulation and analytical strategies can accelerate your oligonucleotide program.